Abstract:Abstract Alterations in the RAS/RAF/MEK/ERK pathway are the most common drivers of oncogenesis. Although MEK is a clinically validated cancer target and several MEK inhibitors have been approved by the FDA, their clinical utility has been limited to BRAF V600 mutant cancers and NF1 mutant neurofibromas. We developed IK-595, a potent inhibitor of the MEK-RAF complex, to overcome the limitations of available MEK inhibitors. IK-595 traps MEK in an inactive complex with all RAF isoforms and blocks RAF-dependent MEK phosphorylation, thereby alleviating CRAF-mediated MEK reactivation that hinders the efficacy of approved MEK inhibitors in RAS/RAF-driven tumors. We demonstrate that IK-595 leads to potent and prolonged inhibition of MEK and ERK1/2 phosphorylation, in KRAS-mutant cancer and NRAS-mutant melanoma models. In addition to trapping all three RAF isoforms, IK-595 stabilizes the interaction of MEK with BRAF Class I, II, and III mutant proteins. This delays the onset of known resistance mechanisms to other MAPK pathway targeting agents, such as CRAF-mediated pathway reactivation and receptor tyrosine kinase upregulation and/or activation. Importantly, IK-595 has a much slower off-rate binding to MEK and retains CRAF longer in an inactive complex with MEK than other MEK/RAF inhibitors allowing for more prolonged target engagement and durable pathway inhibition in RAS/RAF mutant cancer cells. Moreover, CRAF-ARAF heterodimerization, which is detected in type II pan-RAF inhibitor-treated KRAS mutant cells as an established resistance mechanism, is not observed upon IK-595 treatment. IK-595 exhibits potent signal agent activity across a wide range of cancer models harboring various RAS/RAF alterations, including lung, pancreatic, colorectal cancer (CRC), melanoma, AML, and others. Strong synergy with inhibitors targeting multiple key mechanisms, both within the RAS/MAPK pathway and across parallel survival pathways, has also been observed in multiple models. Key to the design of IK-595 is its PK profile that enables transient high plasma drug exposure and flexible dosing schedules. Intermittent dosing of IK-595 every other day (QOD) or every three days (Q3D) in KRAS mutant mouse tumor models shows similar efficacy and improved tolerability compared to daily dosing (QD), affording a larger therapeutic window. Preclinical pharmacology studies provide clear guidance to the clinical development plan of IK-595, where flexible dosing schedules and multiple expansion cohorts in RAS/RAF altered patient populations will be explored. IK-595 is a novel MEK-RAF complex inhibitor that prolongs pathway inhibition, minimizing the potential for resistance, while providing an optimal therapeutic window for patients with RAS/RAF-driven cancer. Citation Format: Eric Haines, Rachel Catterall, Victor De Jesus, Bin Li, Sarah R Wessel, Jill Cavanaugh, Michael Burke, Joseph D Manna, Okzana Zavidij, Ao Yang, Lan Xu, Sergio Santillana, Jeffrey Ecsedy, X. Michelle Zhang, Sabine K Ruppel. IK-595, a best-in-class MEK-RAF complex inhibitor, drives broad and potent anti-tumor activity in RAS/RAF-driven tumors [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr B155.

Erianin suppresses constitutive activation of MAPK signaling pathway by inhibition of CRAF and MEK1/2

Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy.

Targeting Extracellular Signal-Regulated Protein Kinase 1/2 (ERK1/2) in Cancer: an Update on Pharmacological Small-Molecule Inhibitors.

Erianin suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK MAPK signaling pathways.

Abstract B155: IK-595, a Best-in-class MEK-RAF Complex Inhibitor, Drives Broad and Potent Anti-Tumor Activity in RAS/RAF-driven Tumors

Abstract PR10: IK-595, a MEK-RAF Complex Inhibitor, Obviates CRAF Mediated Resistance Resulting in Superior RAS/MAPK Pathway Inhibition and Anti-Tumor Activity in RAS/RAF Altered Cancers

BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma

Simultaneous blocking of the pan-RAF and S100B pathways as a synergistic therapeutic strategy against malignant melanoma

Erianin inhibits the growth and metastasis through autophagy-dependent ferroptosis in KRAS G13D colorectal cancer

Erianin Inhibits the Growth and Metastasis Through Autophagy-Dependent Ferroptosis in KRASG13D Colorectal Cancer

Anticancer Effects of Combinational Treatment with BRAFV600E Sirna and PI3K Pathway Inhibitors in Melanoma Cell Lines Harboring BRAFV600E.

Erianin inhibits human lung cancer cell growth via PI3K /Akt/ mTOR pathway in vitro and in vivo

Erianin inhibits the progression of pancreatic cancer by directly targeting AKT and ASK1

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway

PO-099 Targeting the Mitogen Activated Protein Kinase ERK5 in Human Melanoma

Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy

Dual Inhibition of Allosteric Mitogen-Activated Protein Kinase (MEK) and Phosphatidylinositol 3-Kinase (PI3K) Oncogenic Targets with a Bifunctional Inhibitor

Abstract 1947: Studies on pMEK inhibitors for the treatment of RAS-mutant cancers as a single agent or combinations

Abstract 3760: HH2710, a Highly Potent and Selective Erk1/2 Inhibitor for the Treatment of Mapk Mutant Tumors